Patents Assigned to Medexgen Co., Ltd.
-
Publication number: 20130089513Abstract: Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate. Also, the present invention discloses a DNA encoding the protein variant, a recombinant expression vector to which the DNA is operably linked, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing the protein variant comprising cultivating the host cell and isolating the protein variant from the resulting culture. Further, the present invention discloses a pharmaceutical composition comprising the protein variant and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 2, 2012Publication date: April 11, 2013Applicant: Medexgen Co., Ltd.Inventors: Yong-Hoon Chung, Hak-sup Lee, Ki-Wan Yi, Youn-Hwa Heo, Jae-Youn Kim
-
Patent number: 8372961Abstract: Disclosed are concatameric proteins comprising two soluble domains, in which the C-terminus of a soluble domain of a biologically active protein is linked to the N-terminus of an identical soluble domain or a distinct soluble domain of a biologically active protein. Also, the present invention discloses dimeric proteins formed by formation of intermolecular disulfide bonds at the hinge region of two monomeric proteins formed by linkage of a concatamer of two identical soluble extracellular regions of proteins involving immune response to an Fc fragment of an immunoglobulin molecule, their glycosylated proteins, DNA constructs encoding the monomeric proteins, recombinant expression plasmids containing the DNA construct, host cells transformed or transfected with the recombinant expression plasmids, and a method of preparing the dimeric proteins by culturing the host cells. Further, the present invention discloses pharmaceutical or diagnostic compositions comprising the dimeric protein or its glycosylated form.Type: GrantFiled: January 22, 2010Date of Patent: February 12, 2013Assignee: Medexgen Co., Ltd.Inventors: Yong-Hoon Chung, Ji-Woong Han, Hye-Ja Lee, Eun-Yong Choi, Jin-Mi Kim
-
Publication number: 20100278827Abstract: Disclosed are concatameric proteins comprising two soluble domains, in which the C-terminus of a soluble domain of a biologically active protein is linked to the N-terminus of an identical soluble domain or a distinct soluble domain of a biologically active protein. Also, the present invention discloses dimeric proteins formed by formation of intermolecular disulfide bonds at the hinge region of two monomeric proteins formed by linkage of a concatamer of two identical soluble extracellular regions of proteins involving immune response to an Fc fragment pf an immunoglobulin molecule, their glycosylated proteins, DNA constructs encoding the monomeric proteins, recombinant expression plasmids containing the DNA construct, host cells transformed or transfected with the recombinant expression plasmids, and a method of preparing the dimeric proteins by culturing the host cells. Further, the present invention discloses pharmaceutical or diagnostic compositions comprising the dimeric protein or its glycosylated form.Type: ApplicationFiled: January 22, 2010Publication date: November 4, 2010Applicant: Medexgen Co., Ltd.Inventors: Yong-Hoon CHUNG, Ji-Woong Han, Hye-Ja Lee, Eun-Yong Choi, Jin-Mi Kim
-
Patent number: 7670602Abstract: Disclosed are concatameric proteins comprising two soluble domains, in which the C-terminus of a soluble domain of a biologically active protein is linked to the N-terminus of an identical soluble domain or a distinct soluble domain of a biologically active protein. Also, the present invention discloses dimeric proteins formed by formation of intermolecular disulfide bonds at the hinge region of two monomeric proteins formed by linkage of a concatamer of two identical soluble extracellular regions of proteins involving immune response to an Fc fragment of an immunoglobulin molecule, their glycosylated proteins, DNA constructs encoding the monomeric proteins, recombinant expression plasmids containing the DNA construct, host cells transformed or transfected with the recombinant expression plasmids, and a method of preparing the dimeric proteins by culturing the host cells. Further, the present invention discloses pharmaceutical or diagnostic compositions comprising the dimeric protein or its glycosylated form.Type: GrantFiled: April 24, 2007Date of Patent: March 2, 2010Assignee: Medexgen Co., LtdInventors: Yong-Hoon Chung, Ji-Woong Han, Hye-Ja Lee, Eun-Yong Choi, Jin-Mi Kim
-
Publication number: 20100041586Abstract: Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate. Also, the present invention discloses a DNA encoding the protein variant, a recombinant expression vector to which the DNA is operably linked, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing the protein variant comprising cultivating the host cell and isolating the protein variant from the resulting culture. Further, the present invention discloses a pharmaceutical composition comprising the protein variant and a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 8, 2009Publication date: February 18, 2010Applicant: MEDEXGEN, CO., LTDInventors: Yong-Hoon Chung, Hak-sup Lee, Ki-Wan Yi, Youn-Hwa Heo, Jae-Youn Kim
-
Patent number: 7569361Abstract: Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate. Also, the present invention discloses a DNA encoding the protein variant, a recombinant expression vector to which the DNA is operably linked, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing the protein variant comprising cultivating the host cell and isolating the protein variant from the resulting culture. Further, the present invention discloses a pharmaceutical composition comprising the protein variant and a pharmaceutically acceptable carrier.Type: GrantFiled: May 27, 2004Date of Patent: August 4, 2009Assignee: Medexgen Co., Ltd.Inventors: Yong-Hoon Chung, Hak-sup Lee, Ki-Wan Yi, Youn-Hwa Heo, Jae-Youn Kim
-
Publication number: 20090011466Abstract: Disclosed are concatameric proteins comprising two soluble domains, in which the C-terminus of a soluble domain of a biologically active protein is linked to the N-terminus of an identical soluble domain or a distinct soluble domain of a biologically active protein. Also, the present invention discloses dimeric proteins formed by formation of intermolecular disulfide bonds at the hinge region of two monomeric proteins formed by linkage of a concatamer of two identical soluble extracellular regions of proteins involving immune response to an Fc fragment of an immunoglobulin molecule, their glycosylated proteins, DNA constructs encoding the monomeric proteins, recombinant expression plasmids containing the DNA construct, host cells transformed or transfected with the recombinant expression plasmids, and a method of preparing the dimeric proteins by culturing the host cells. Further, the present invention discloses pharmaceutical or diagnostic compositions comprising the dimeric protein or its glycosylated form.Type: ApplicationFiled: April 24, 2007Publication date: January 8, 2009Applicant: MEDEXGEN CO., LTD.Inventors: Yong-Hoon CHUNG, Ji-Woong HAN, Hye-Ja LEE, Eun-Yong CHOI, Jin-Mi KIM
-
Patent number: 7229962Abstract: Disclosed are concatameric proteins comprising two soluble domains, in which the C-terminus of a soluble domain of a biologically active protein is linked to the N-terminus of an identical soluble domain or a distinct soluble domain of a biologically active protein. Also, the present invention discloses dimeric proteins formed by formation of intermolecular disulfide bonds at the hinge region of two monomeric proteins formed by linkage of a concatamer of two identical soluble extracellular regions of proteins involving immune response to an Fc fragment of an immunoglobulin molecule, their glycosylated proteins, DNA constructs encoding the monomeric proteins, recombinant expression plasmids containing the DNA construct, host cells transformed or transfected with the recombinant expression plasmids, and a method of preparing the dimeric proteins by culturing the host cells. Further, the present invention discloses pharmaceutical or diagnostic compositions comprising the dimeric protein or its glycosylated form.Type: GrantFiled: July 26, 2002Date of Patent: June 12, 2007Assignee: Medexgen Co., Ltd.Inventors: Yong-Hoon Chung, Ji-Woong Han, Hye-Ja Lee, Eun-Yong Choi, Jin-Mi Kim